Table 1 Trials of ≥12 months follow-up in patients with chronic kidney disease in which left ventricular mass was reduced in the intervention group relative to the control group^a

Levin, 2005 [37]

ESA/higher vs. lower hemoglobin target

1

85

3

87

24

−0.20

Parfrey, 2005 [38]

ESA/higher vs. lower hemoglobin target

13

296

20

300

24

−0.12

Macdougall, 2007 [43]

ESA/higher vs. lower hemoglobin target

1

65

6

132

36

−0.25

Ritz, 2007 [44]

ESA/higher vs. lower hemoglobin target

0

89

0

83

15

−0.05

Pappas, 2008 [46]

ESA/higher vs. lower hemoglobin target

1

15

3

16

12

−0.97

Cianciaruso, 2008 [45]

ESA/higher vs. lower hemoglobin target

1

46

0

49

24

−0.07

Suzuki, 2002 [34]

RAASi vs. placebo or standard treatment

without LVH, 5 mg benazepril

0

12

0

12

12

−0.52

without LVH, 2.5 mg benazepril

0

12

0

12

12

−0.43

with LVH, 5 mg benazepril

0

12

0

12

12

−0.44

with LVH, 2.5 mg benazepril

0

12

0

12

12

−0.15

London, 1994 [29]

RAASi vs. placebo or standard treatment

0

16

0

16

12

−0.57

Suzuki, 2003 [35]

RAASi vs. placebo or standard treatment

0

14

0

10

12

−0.61

Kanno, 2004 [36]

RAASi vs. placebo or standard treatment

0

12

0

12

12

−1.05

Yu, 2006 [40]

RAASi vs. placebo or standard treatment

1

24

0

22

12

−0.51

Mitsuhashi, 2009 [49]

RAASi vs. placebo or standard treatment

0

20

0

20

12

−0.89

Zeltner, 2008 [47]

RAASi vs. placebo or standard treatment

0

23

0

23

36

−0.01

Yilmaz, 2010 [54]

RAASi vs. placebo or standard treatment

0

56

1

56

12

−0.18

Ito, 2014 [70]

RAASi vs. placebo or standard treatment

2

78

5

80

24

−0.34

Ulusoy, 2010 [53]

RAASi vs. other RAASi

0

19

0

13

12

−0.49

Schrander-vd Meer, 1999 [30]

Convective HD vs. standard HD

0

12

0

12

12

−0.69

Alvestrand, 2011 [56]

Convective HD vs. standard HD

2

27

3

21

24

−0.31

Ohtake, 2012 [64]

Convective HD vs. standard HD

0

13

0

9

12

−0.26

Mostovaya, 2014 [72]

Convective HD vs. standard HD

41

358

51

356

12

−0.11

Katopodis, 2009 [48]

≥4x vs. <4x/week HD

0

9

0

9

12

−0.25

Chertow, 2010 [51]

≥4x vs. <4x/week HD

5

125

9

120

12

−0.26

Rocco, 2011 [61]

≥4x vs. <4x/week HD

2

45

1

42

12

−0.20

Chen, 2011 [57]

HD + hemoperfusion vs. HD

6

51

14

49

24

−5.50

Hur, 2013 [67]

Fluid management vs. standard HD

2

78

4

78

12

−0.39

Whalley, 2013 [68]

Early vs. later dialysis initiation

2

91

1

91

12

−0.20

Odudu, 2015 [74]

Individual dialysate cooling vs. standard

2

36

1

37

12

−0.34

Liu, 2016 [76]

Reduced dialysate sodium

3

32

2

32

12

−0.55

Marshall, 2020 [82]

Reduced dialysate sodium

2

49

1

50

12

−0.15

Jardine, 2017 [78]

Extended HD vs. standard

5

100

2

100

12

−0.19

Howden, 2013 [66]

Exercise vs. usual activity

0

41

0

42

12

−0.06

Schrier, 2002 [33]

Lower vs. higher blood pressure target

1

42

1

37

84

−0.92

Nakamura, 2002 [31]

Dilazep vs. placebo

0

20

0

20

12

−0.23

Hotu, 2010 [52]

Nurse/community vs. physician/clinic

2

33

0

32

12

−0.69

Zamboli, 2011 [62]

Furosemide vs. no furosemide

0

20

0

20

12

−0.55

Higuchi, 2016 [75]

Levocarnitine vs. no levocarnitine

5

110

7

112

12

−0.40

Lin, 2016 [77]

Spironolactone vs. placebo

12

125

25

128

24

−0.55

Miskulin, 2018 [79]

Lower vs. higher blood pressure target

4

62

1

64

12

−0.05

Fujii, 2018 [85]

Lanthanum carbonate vs. calcium carbonate

1

50

1

55

18

−0.07

Rutherford, 2021 [86]

Allopurinol vs. placebo

2

40

5

40

12

−0.10

Dorr, 2021 [84]

Etelcalcitide vs. alfacalcidol

2

32

1

30

12

−0.40

Edwards, 2021 [83]

Spironolactone vs. chlorthalidone

0

77

0

77

40

−0.12

Total or Median^a

121

2584

168

2606

12

−0.285